Company Analysis
Sign in

Black Diamond Therapeutics, Inc. (BDTX)

Nasdaq: BDTX · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2017
Full chart Alerts Compare
Grade5.9
◀ Past 5.7● Present 7.1▶ Future 5.0
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

2 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Black Diamond Therapeutics, Inc.’s names, not what it holds today.

Patents granted
2
2 utility, 1976 to Dec 31, 2025
Granted in 2025
1
in the last year the record reads
Applications published
9
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'21'22'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Black Diamond Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
6 published
Black Diamond Therapeutics, Inc. its own name
US, as the owner printed on each patent
2 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 7, 202512,435,046Alkynyl quinazoline compoundsOrganic fine chemistryBlack Diamond Therapeutics, Inc.
Jun 15, 202111,034,672Tyrosine kinase inhibitor compositions, methods of making and methods of useOrganic fine chemistryBlack Diamond Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jan 16, 20252025/00179146-AZA-QUINOLINE DERIVATIVES AND RELATED USESPharmaceuticalsBlack Diamond Therapeutics, Inc.
Dec 26, 20242024/0425492POLYMORPHS AS ERBB INHIBITORSOrganic fine chemistryBlack Diamond Therapeutics, Inc.
Nov 7, 20242024/0368181QUINOXALINE DERIVATIVES AND USES THEREOFOrganic fine chemistryBlack Diamond Therapeutics, Inc.
Sep 26, 20242024/03177526-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USESPharmaceuticalsBlack Diamond Therapeutics, Inc.
Mar 7, 20242024/0075042METHOD OF TREATING CANCERS WITH ALKYNE SUBSTITUTED QUINAZOLINE DERIVATIVESPharmaceuticalsBlack Diamond Therapeutics, Inc.
Nov 17, 20222022/0363666TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USEOrganic fine chemistryBlack Diamond Therapeutics, Inc.
Sep 22, 20222022/0298120ALKYNYL QUINAZOLINE COMPOUNDSOrganic fine chemistryBlack Diamond Therapeutics, Inc. · patent 12,435,046 granted from it
Feb 10, 20222022/0041613TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USEOrganic fine chemistryBlack Diamond Therapeutics, Inc.
Jun 3, 20212021/0163447TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USEOrganic fine chemistryBlack Diamond Therapeutics, Inc. · patent 11,034,672 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Organic fine chemistry 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BDTX · research, not advice